HPV-driven oropharyngeal cancer burden in Paris and its region (ILE DE FRANCE) from 1981 TO 2021.

Cancer(s) Epidemiology France Human papillomavirus (HPV) Neoplasm(s) Oral/oropharynx/oropharyngeal Prevalence Tonsil/tonsillar

Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
19 Jun 2024
Historique:
received: 12 02 2024
revised: 10 06 2024
accepted: 14 06 2024
medline: 21 6 2024
pubmed: 21 6 2024
entrez: 20 6 2024
Statut: aheadofprint

Résumé

France has the sixth highest incidence of oropharyngeal cancer (OPC) in Europe, but the epidemiological impact of high-risk HPV (HR-HPV) remains poorly documented. The objective of our study was to assess the proportion of OPCs caused by HR-HPV in Paris, and its suburbs, over the four past decades. This area accounts for almost one-fifth of the total population of France. OPCs diagnosed in 1981, 1986, 1991, 1996, 2001, 2006, 2011, 2016 and 2020/2021 in two of the main referral cancer centers for HNCs in Paris and its suburbs were retrieved from the tumor biobanks. HPV status was determined by p16-staining and HPV-DNA detection. Samples were considered HPV-driven if both assays were positive. Results were compared to the French cancer registry data. Samples from 697 OPC patients were assessed (including 82 % of all samples diagnosed in 2001, 2006, 2011, 2016, 2021). The proportion of HPV-driven cases rose from 2.7 % to 53 % between 1981 and 2021. HPV16 was the dominant genotype during the study period. Of patients with HPV-driven OPC, 81 % were male and 42 % were smokers versus 80 % and 92 % in their HPV-negative counterparts. The age of OPC patients increased significantly, during the study period, independent of their HPV status CONCLUSION: The proportion of HPV-driven OPCs has significantly increased in Paris and its suburbs, during the last four decades. OPCs has become the 2nd predominant type of head and neck cancer, in France. This may be linked to the rise in HPV-driven cases and the decrease of tobacco and alcohol consumption in men.

Sections du résumé

BACKGROUND BACKGROUND
France has the sixth highest incidence of oropharyngeal cancer (OPC) in Europe, but the epidemiological impact of high-risk HPV (HR-HPV) remains poorly documented. The objective of our study was to assess the proportion of OPCs caused by HR-HPV in Paris, and its suburbs, over the four past decades. This area accounts for almost one-fifth of the total population of France.
METHODS METHODS
OPCs diagnosed in 1981, 1986, 1991, 1996, 2001, 2006, 2011, 2016 and 2020/2021 in two of the main referral cancer centers for HNCs in Paris and its suburbs were retrieved from the tumor biobanks. HPV status was determined by p16-staining and HPV-DNA detection. Samples were considered HPV-driven if both assays were positive. Results were compared to the French cancer registry data.
RESULTS RESULTS
Samples from 697 OPC patients were assessed (including 82 % of all samples diagnosed in 2001, 2006, 2011, 2016, 2021). The proportion of HPV-driven cases rose from 2.7 % to 53 % between 1981 and 2021. HPV16 was the dominant genotype during the study period. Of patients with HPV-driven OPC, 81 % were male and 42 % were smokers versus 80 % and 92 % in their HPV-negative counterparts. The age of OPC patients increased significantly, during the study period, independent of their HPV status CONCLUSION: The proportion of HPV-driven OPCs has significantly increased in Paris and its suburbs, during the last four decades. OPCs has become the 2nd predominant type of head and neck cancer, in France. This may be linked to the rise in HPV-driven cases and the decrease of tobacco and alcohol consumption in men.

Identifiants

DOI: 10.1016/j.canep.2024.102603 PMID: 38901087
pubmed: 38901087
pii: S1877-7821(24)00082-1
doi: 10.1016/j.canep.2024.102603
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102603

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have nothing to disclose

Auteurs

Haitham Mirghani (H)

Department of Otorhinolaryngology and Head and Neck surgery, Georges Pompidou European hospital, Université Paris Cité, 20 rue Leblanc, Paris, France. Electronic address: haitham.mirghani@aphp.fr.

Alexandre Tendron (A)

Department of Head and Neck oncology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.

Anne Auperin (A)

Department of Epidemiology and Statistics, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.

Odile Casiraghi (O)

Department of Pathology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.

Marion Classe (M)

Department of Pathology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.

Cécile Badoual (C)

Department of Pathology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, Paris, France.

Clémence Legoupil (C)

Department of Epidemiology and Statistics, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.

Julien Puech (J)

Department of Pathology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, Paris, France.

David Veyer (D)

Department of Pathology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, Paris, France.

Véronique Dalstein (V)

Laboratory of Biopathology, Reims University Hospital - Maison Blanche, Reims-Champagne-Ardenne University, Reims 51092, France.

Hélène Pere (H)

Department of Pathology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, Paris, France.

Philippe Gorphe (P)

Department of Head and Neck oncology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.

Classifications MeSH